Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research Article

β-Galactosidase Treatment Is a Common First-stage Modification of the Three Major Subtypes of Gc Protein to GcMAF

YOSHIHIRO UTO, SYOTA YAMAMOTO, HIROTAKA MUKAI, NORIKO ISHIYAMA, RYOTA TAKEUCHI, YOSHINORI NAKAGAWA, KEIJI HIROTA, HIROSHI TERADA, SHINYA ONIZUKA and HITOSHI HORI
Anticancer Research June 2012, 32 (6) 2359-2364;
YOSHIHIRO UTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: uto@bio.tokushima-u.ac.jp
SYOTA YAMAMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROTAKA MUKAI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIKO ISHIYAMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOTA TAKEUCHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHINORI NAKAGAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEIJI HIROTA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI TERADA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINYA ONIZUKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HITOSHI HORI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The 1f1f subtype of the group-specific component (Gc) protein is converted into Gc protein-derived macrophage-activating factor (GcMAF) by enzymatic processing with β-galactosidase and sialidase. We previously demonstrated that preGc1f1fMAF, a full Gc1f1f protein otherwise lacking a galactosyl moiety, can be converted to GcMAF by treatment with mouse peritoneal fluid. Here, we investigated the effects of the β-galactosidase-treated 1s1s and 22 subtypes of Gc protein (preGc1s1sMAF and preGc22MAF) on the phagocytic activation of mouse peritoneal macrophages. Results: We demonstrated the presence of Gal-GalNAc disaccharide sugar structures in the Gc1s1s protein by western blotting using peanut agglutinin and Helix pomatia agglutinin lectin. We also found that preGc1s1sMAF and preGc22MAF significantly enhanced the phagocytic activity of mouse peritoneal macrophages in the presence and absence of mouse peritoneal fluid. Conclusion: We demonstrate that preGc1s1sMAF and preGc22MAF proteins can be used as effective macrophage activators.

  • Human serum Gc protein
  • β-galactosidase-treatment
  • 1s1s and 22 subtypes
  • phagocytic activity
  • mouse peritoneal macrophages
  • group-specific component protein

The group-specific component (Gc) protein, a vitamin D-binding protein (DBP), Gc globulin, is a 53-kDa human plasma protein (1), of which there are six major subtypes, the homodimers and heterodimers of Gc1f, Gc1s, and Gc2 (2). The 1f1f subtype of the Gc protein (Gc1f1f protein) contains a branched trisaccharide with a galactose (Gal) and a sialic acid (SA) moiety bound to N-acetylgalactosamine (GalNAc) attached to the core protein (3). Furthermore, the 1s1s subtype of the Gc protein (Gc1s1s protein) contains two different sugar structures: a branched trisaccharide with Gal and a mannose (MA) moiety bound to GalNAc (4), or a linear trisaccharide with SA-Gal-GalNAc (5, 6). The 22 subtype of the Gc protein (Gc22 protein) contains a linear Gal-GalNAc disaccharide sugar structure (3). In an inflammatory response, the terminal Gal and SA of the Gc1f1f protein were hydrolyzed by membrane-bound β-galactosidase on an activated B-cell and sialidase on a T-cell, respectively, to produce Gc protein-derived macrophage-activating factor (GcMAF) (7). GcMAF has some interesting biological activities, such as promotion of macrophage activation via superoxide generation (8, 9), and phagocytic activation (10), in addition to antiangiogenic (11, 12) and antitumor activities (13-15). GcMAF has also been shown to have clinical activity against metastatic colorectal, metastatic breast, and prostate cancer, with additional activities in non-anemic HIV-infected patients (16-19).

Until now, the interesting GcMAF biological activity data, concerned only the 1f1f GcMAF subtype, although the biological or clinical applications for Gc1s1s and Gc22 protein-derived GcMAF have not been reported. If GcMAF is an endogenous macrophage activator, all Gc protein subtypes should have the possibility of being converted into GcMAF. We previously demonstrated that preGc1f1fMAF, a full Gc1f1f protein lacking only a galactosyl moiety, can be converted to GcMAF by treatment with mouse peritoneal fluid (20). We hypothesized that if β-galactosidase treatment could be applied to all Gc protein subtypes (1f, 1s and 2), the clinical use of GcMAF could be attained from all human serum. Here, we present the effect of β-galactosidase-treated Gc1s1s and Gc22 proteins (preGc1s1sMAF and preGc22MAF) on the phagocytic activation of mouse peritoneal macrophages.

Materials and Methods

Materials. Lipopolysaccharide (LPS; from Escherichia coli O128:B12) and Sepharose CL-6B (cross-linked) were purchased from Sigma-Aldrich Japan Co. Ltd. (Tokyo, Japan). 25-Hydroxyvitamin D3 [25(OH)D3] and other biochemical-grade chemicals were purchased from WAKO Pure Chemical Industries Co. Ltd. (Osaka, Japan).

Preparation of human serum Gc1s1s and Gc22 protein. The Gc1s1s and Gc22 proteins were prepared as reported by Link et al. (21). Briefly, serum from healthy humans containing Gc1s1s or Gc22 proteins (each 7.0 ml) was diluted 1:1 with column buffer (50 mM Tris-HCl, 1.5 mM EDTA, 150 mM NaCl, 0.1% Triton X-100; pH 7.4) and applied to a 25(OH)D3-Sepharose column which was prepared in our laboratory according to the method reported by Link et al. (21). The column was washed with 300 ml of column buffer. The protein remaining on the matrix was eluted with 6 M guanidine-HCl, and a 1-ml fraction was collected. Fractions of the protein peak encompassing the guanidine-eluted fraction were pooled and dialyzed with 10 mM sodium phosphate (pH 7.0). Subsequently, a hydroxyapatite column with a volume of 5 ml (Bio-Scale Mini CHT Type II Cartridge; Bio-Rad Laboratories, Tokyo, Japan) was equilibrated with 10 mM sodium phosphate (pH 7.0). The dialyzed sample obtained following 25(OH)D3-Sepharose column chromatography was applied to the column. A linear gradient elution from 10 mM sodium phosphate to 200 mM sodium phosphate (pH 7.0) was used for column chromatography. Fractions were collected and concentrated with a centricon-concentrating unit (30,000 MWCO; Nihon Millipore Co. Ltd., Tokyo, Japan), and their protein concentrations were determined using the bicinchoninic acid (BCA) method (Pierce Chemical Co., Rockford, IL, USA). Bovine serum albumin (BSA) was used as a standard. The yields of purified Gc1s1s and Gc22 proteins were 2.294 mg and 1.867 mg, respectively.

Preparation of preGc1s1sMAF and preGc22MAF. The purified Gc1s1s and Gc22 proteins (200 μg) were incubated with 1000 mU β-galactosidase (grade III from bovine liver; Sigma-Aldrich Japan Co. Ltd., Osaka, Japan) in 100 mM sodium phosphate buffer (pH 7.0) in an Eppendorf tube at 37.5°C for 3 h. The reaction mixture was mixed with 25(OH)D3-Sepharose beads and was stirred for 10 min at room temperature using a vortex mixer to separate the β-galactosidase. The solution was concentrated using a microcon-concentration unit (10,000 MWCO; Nihon Millipore Co. Ltd., Tokyo, Japan). The protein concentrations were determined using the BCA method, and the yields of preGc1s1sMAF and preGc22MAF were calculated as being 80.2 μg and 57.8 μg, respectively.

Western blotting. The Gc1s1s and Gc22 proteins and the preGc1s1sMAF and preGc22MAF subtypes were subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions and subsequently electroblotted onto a polyvinylidene fluoride (PVDF) membrane. Non-specific binding was blocked by overnight incubation in Tris-buffered saline (pH 7.4) containing 0.1% Tween 20 and 1% BSA at 4°C. The membranes were then probed with anti-human Gc globulin (DakoCytomation Co. Ltd., Kyoto, Japan) against the Gc1s1s and Gc22 proteins, and with Peanut Agglutinin (PNA) lectin (Arachis hypogaea, biotin-conjugated; Sigma-Aldrich Japan Co. Ltd., Osaka, Japan) and Helix pomatia (HPA) lectin (Helix pomatia, biotin-conjugated; Sigma-Aldrich Japan Co. Ltd., Osaka, Japan) for the Gc1s1s and Gc22 protein subtypes preGc1s1sMAF and preGc22MAF. After extensive washing, the blots were incubated with the secondary antibody [horseradish peroxidase (HRP)-labeled anti-rabbit IgG and electrochemiluminescence (ECL) streptavidin-HRP conjugate; GE Healthcare Japan Co., Tokyo, Japan]. The blots were developed using an ECL western blotting detection system (GE Healthcare Japan Co.). The visualization and quantification of the western blot bands was achieved using a LumiCube chemiluminescence analyzer and the JustTLC image analysis software (Liponics Inc., Tokyo, Japan).

Isolation and culture of mouse peritoneal macrophages. Resident mouse peritoneal macrophages were collected from 8-week-old female mice from the Institute for Cancer Research (ICR). After centrifugation at 1,000 rpm, at 4°C, for 15 min, macrophages were collected and cultured in 24-well plates at a density of 5×105 cells/well in serum-free RPMI-1640 (Life Technologies Japan Ltd., Tokyo, Japan) for 1 h. The cultured cells were then washed three times with serum-free RPMI-1640 to separate adherent macrophages from non-adherent cells, such as T- and B-cells. The macrophages were cultured for 15 h, following which, the phagocytosis assay was performed as described below.

Phagocytosis assay for preGc1s1sMAF and preGc22MAF. Mouse peritoneal cells were layered onto coverslips in a 24-well plate. After 3 h of treatment (treated preGc1s1sMAF and preGc22MAF were pre-incubated with peritoneal fluid at 37°C for 1 h), the cultures were assayed for phagocytic activity. Sheep red blood cells (SRBCs; Nippon Bio-Supp. Center Co., Tokyo, Japan) were opsonized by rabbit hemolytic serum (anti-sheep red blood cells; Cosmo Bio Co., Tokyo, Japan). Opsonized SRBCs (0.5%) in serum-free RPMI-1640 were overlaid onto each macrophage-coated coverslip and were cultured for 1.5 h. The non-internalized erythrocytes were lysed by immersing the coverslip into a hypotonic solution (1/5 phosphate-buffered saline). The macrophages were fixed with methanol, air-dried, and stained with Giemsa stain. The number of phagocytosed erythrocytes per cell was determined microscopically; 250 macrophages were counted for each data point. The data are expressed in terms of the phagocytotic index (PI), which is defined as the percentage of macrophages with ingested erythrocytes multiplied by the average number of erythrocytes ingested per macrophage.

Statistical analysis. Data are expressed as the mean ±SD. The significance of the differences between the results of the independent experiments was analyzed using the Student's t-test. A p-value of <0.05 was considered significant.

Results

Preparation and identification of preGc1s1sMAF and preGc22MAF. We obtained 2.294 mg of Gc1s1s protein and 1.867 mg of Gc22 protein from 7.0 ml of human serum using a 25(OH)D3 affinity column. Figure 1A shows the SDS-PAGE gel and the western blot of the purified Gc1s1s and Gc22 proteins. A single band was detected on staining with Coomassie brilliant blue (CBB) and after probing with an anti-human Gc globulin antibody. The purified Gc1s1s and Gc22 proteins were treated with β-galactosidase and then checked for purity by western blot using PNA and HPA lectin in order to identify whether Gal had been removed and GalNAc had appeared. We observed the disappearance of the PNA lectin-stained preGc1s1sMAF (reduction in the band concentration from 55.98 to 0.25 counts) and the preGc22MAF (reduction in the band concentration from 157.56 to 1.59 counts) bands, which had affinity for the Gal-GalNAc moiety (Figure 1B). We also observed the HPA lectin-stained preGc1s1sMAF (increase in the band concentration from 0.52 to 141.36 counts) band that had affinity for the GalNAc-end. The reason for this, however, remains unknown, although positive bands were present for the Gc22 and preGc22MAF proteins (a slight increase in the band concentration from 121.05 to 128.10 counts). These data indicate that both preGc1s1sMAF and preGc22MAF contained a GalNAc moiety.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blot analysis of preGc1s1sMAF and preGc22MAF. A: SDS-PAGE gel stained with coomassie brilliant blue (CBB) and a western blot probed with anti-human Gc globulin against purified Gc1s1s and Gc22 proteins. B: Western blot of preGc1s1sMAF and preGc22MAF using Peanut Agglutinin (PNA) lectin (affinity for Gal-GalNAc disaccharide) and Helix pomatia (HPA) lectin (affinity for GalNAc moiety). The values below blots represent the concentrations for each band.

Phagocytic activity of preGc1s1sMAF and preGc22MAF toward mouse peritoneal macrophages. We examined phagocytic activation or macrophage activation by preGc1s1sMAF and preGc22MAF toward mouse peritoneal macrophages, in order to evaluate their macrophage-activating effects. Figure 2A shows significant phagocytic activation by 10 ng of preGc1s1sMAF on treatment with mouse peritoneal fluid, as compared with the control (without mouse peritoneal fluid). The PI of 1.44 for 10 ng of preGc1s1sMAF corresponded to that of 10 ng of Gc1f1fMAF (PI=1.53) and 1 μg of LPS (PI=1.59). Gc1s1s protein did not result in significant phagocytic activation with or without mouse peritoneal fluid treatment (Figure 2B). Figure 3A shows significant phagocytic activation by 10 ng of preGc22MAF on treatment with mouse peritoneal fluid compared with the control (without mouse peritoneal fluid). The PI of 1.58 for 10 ng of preGc22MAF corresponded to that of 10 ng of Gc1f1fMAF (PI=1.69) and 1 μg of LPS (PI=1.99). Gc22 protein did not result in significant phagocytic activation with or without mouse peritoneal fluid treatment (Figure 3B).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Phagocytic activity of mouse peritoneal macrophages observed using preGc1s1sMAF (A) and Gc1s1s protein (B), treated or not treated with mouse peritoneal fluid. All experiments were performed in triplicate. Each bar represents the mean (±SD). *p<0.05.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Phagocytic activity of mouse peritoneal macrophages observed using preGc22MAF (A) and Gc22 protein (B) treated or not treated with mouse peritoneal fluid. All experiments were performed in triplicate. Each bar represents the mean (±SD). *p<0.05.

Discussion

We prepared preGc1s1sMAF and preGc22MAF by β-galactosidase treatment of purified Gc1s1s and Gc22 proteins and evaluated their effects on macrophage activation. Using western blotting with PNA and HPA lectin, we propose, for the first time, that the Gal-GalNAc disaccharide sugar structure exists as part of the Gc1s1s protein. Dr. Yamamoto suggested that the sugar moiety of the Gc1s1s protein contained a branched trisaccharide with a Gal and an MA moiety bound to GalNAc (4), while Borges and Ravnsborg proposed an alternative sugar structure for the Gc1s1s protein, consisting of a linear SA-Gal-GalNAc trisaccharide, by mass spectrometry (5, 6). We presumed from these results that post-modification of SA or MA might not be a stoichiometric reaction. We have demonstrated that the Gc1s1s protein can be a potential precursor of GcMAF when subjected to β-galactosidase processing, and have supported the previously proposed activation mechanism that Gc22 protein containing a linear Gal-GalNAc disaccharide is directly converted into the macrophage activator (GcMAF) by β-galactosidase treatment alone.

In conclusion, we have demonstrated that three major subtypes of β-galactosidase-treated human serum Gc protein can be used as effective macrophage activators in vivo.

Acknowledgements

We thank the staff at the Health Service Center of the University of Tokushima for collecting blood samples from healthy volunteers.

  • Received April 4, 2012.
  • Revision received May 15, 2012.
  • Accepted May 16, 2012.
  • Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Daiger SP
    : Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci USA 72: 2076-2080, 1975.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Svasti J
    : Molecular basis for the three major forms of human serum vitamin D binding protein (group-specific component). Biochem 18: 1611-1617, 1979.
    OpenUrlPubMed
  3. ↵
    1. Yamamoto N,
    2. Homma S
    : Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88: 8539-8543, 1991.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Yamamoto N
    : Macrophage activating factor from vitamin D binding protein. US Patent 5,326,749, July 5, 1994.
  5. ↵
    1. Borges CR,
    2. Jarvis JW,
    3. Oran PE,
    4. Nelson RW
    : Population studies of vitamin D binding protein microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent O-glycosylation patterns. J Proteome Res 7: 4143-4153, 2008.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Ravnsborg T,
    2. Olsen DT,
    3. Thysen AH,
    4. Christiansen M,
    5. Houen G,
    6. Højrup P
    : The glycosylation and characterization of the candidate Gc macrophage-activating factor. Biochim Biophys Acta 1804: 909-917, 2010.
    OpenUrlPubMed
  7. ↵
    1. Yamamoto N,
    2. Kumashiro R
    : Conversion of vitamin D3 binding protein (group-specific component) to a macrophage-activating factor by the stepwise action of beta-galactosidase of B-cells and sialidase of T-cells. J Immunol 151: 2794-2802, 1993.
    OpenUrlAbstract
  8. ↵
    1. Yamamoto N,
    2. Lindsay DD,
    3. Naraparaju VR,
    4. Ireland RA,
    5. Popoff SN
    : A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats. J Immunol 15: 5100-5107, 1994.
    OpenUrl
  9. ↵
    1. Mohamad SB,
    2. Nagasawa H,
    3. Uto Y,
    4. Hori H
    : Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities. Anticancer Res 22: 4297-4300, 2002.
    OpenUrlPubMed
  10. ↵
    1. Nagasawa H,
    2. Sasaki H,
    3. Uto Y,
    4. Kubo S,
    5. Hori H
    : Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein. Anticancer Res 24: 3361-3366, 2004.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kanda S,
    2. Mochizuki Y,
    3. Miyata Y,
    4. Kanetake H,
    5. Yamamoto N
    : Effects of vitamin D3-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst 94: 1311-1319, 2002.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Kisker O,
    2. Onizuka S,
    3. Becker CM,
    4. Fannon M,
    5. Flynn E,
    6. D'Amato R,
    7. Zetter B,
    8. Folkman J,
    9. Ray R,
    10. Swamy N,
    11. Pirie-Shepherd S
    : Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 5: 32-40, 2003.
    OpenUrlPubMed
  13. ↵
    1. Koga Y,
    2. Naraparaju VR,
    3. Yamamoto N
    : Antitumor effect of vitamin D-binding protein-derived macrophage-activating factor on Ehrlich ascites tumor-bearing mice. Proc Soc Exp Biol Med 220: 20-26, 1999.
    OpenUrlAbstract/FREE Full Text
    1. Mohamad SB,
    2. Nagasawa H,
    3. Sasaki H,
    4. Uto Y,
    5. Nakagawa Y,
    6. Kawashima K,
    7. Hori H
    : Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity. Anticancer Res 23: 4451-4457, 2003.
    OpenUrlPubMed
  14. ↵
    1. Nonaka K,
    2. Onizuka S,
    3. Ishibashi H,
    4. Uto Y,
    5. Hori H,
    6. Nakayama T,
    7. Matsuura N,
    8. Kanematsu T,
    9. Fujioka H
    : Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice. J Surg Res 172: 116-122, 2012.
    OpenUrlPubMed
  15. ↵
    1. Yamamoto N,
    2. Suyama H,
    3. Nakazato H,
    4. Yamamoto N,
    5. Koga Y
    : Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage activating factor, GcMAF. Cancer Immunol Immunother 57: 1007-1016, 2008.
    OpenUrlCrossRefPubMed
    1. Yamamoto N,
    2. Suyama H,
    3. Yamamoto N,
    4. Ushijima N
    : Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer 122: 461-467, 2008.
    OpenUrlCrossRefPubMed
    1. Yamamoto N,
    2. Suyama H,
    3. Yamamoto N
    : Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Transl Oncol 1: 65-72, 2008.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Yamamoto N,
    2. Ushijima N,
    3. Koga Y
    : Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). J Med Virol 81: 16-21, 2009.
    OpenUrlPubMed
  17. ↵
    1. Uto Y,
    2. Yamamoto S,
    3. Takeuchi R,
    4. Nakagawa Y,
    5. Hirota K,
    6. Terada H,
    7. Onizuka S,
    8. Nakata E,
    9. Hori H
    : Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages. Anticancer Res 31: 2489-2492, 2011.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Link RP,
    2. Perlman KL,
    3. Pierce EA,
    4. Schnoes HK,
    5. DeLuca HF
    : Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography. Anal Biochem 157: 262-269, 1986.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 32 (6)
Anticancer Research
Vol. 32, Issue 6
June 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
β-Galactosidase Treatment Is a Common First-stage Modification of the Three Major Subtypes of Gc Protein to GcMAF
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
β-Galactosidase Treatment Is a Common First-stage Modification of the Three Major Subtypes of Gc Protein to GcMAF
YOSHIHIRO UTO, SYOTA YAMAMOTO, HIROTAKA MUKAI, NORIKO ISHIYAMA, RYOTA TAKEUCHI, YOSHINORI NAKAGAWA, KEIJI HIROTA, HIROSHI TERADA, SHINYA ONIZUKA, HITOSHI HORI
Anticancer Research Jun 2012, 32 (6) 2359-2364;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
β-Galactosidase Treatment Is a Common First-stage Modification of the Three Major Subtypes of Gc Protein to GcMAF
YOSHIHIRO UTO, SYOTA YAMAMOTO, HIROTAKA MUKAI, NORIKO ISHIYAMA, RYOTA TAKEUCHI, YOSHINORI NAKAGAWA, KEIJI HIROTA, HIROSHI TERADA, SHINYA ONIZUKA, HITOSHI HORI
Anticancer Research Jun 2012, 32 (6) 2359-2364;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Degalactosylated/Desialylated Bovine Colostrum Induces Macrophage Phagocytic Activity Independently of Inflammatory Cytokine Production
  • Antitumor Effect of Degalactosylated Gc-Globulin on Orthotopic Grafted Lung Cancer in Mice
  • Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity
  • Google Scholar

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire